Compass Therapeutics (CMPX) announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. Most recently, he served as Executive Vice President, Chief Operating Officer & Chief Financial Officer at Trevena (TRVN).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMPX:
- Compass downgrade ‘curious,’ presents upside, says H.C. Wainwright
- Compass Therapeutics downgraded to Market Perform from Outperform at Leerink
- Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress
- Compass Therapeutics price target raised to $7 from $5 at Ladenburg
- Compass Therapeutics reports Q3 EPS (8c), consensus (11c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
